A CASE OF COMMON BILE-DUCT STONE WITH CHOLANGITIS PRESENTING AN EXTRAORDINARILY HIGH SERUM CA19-9 VALUE

被引：22

作者：

MUROHISA, T

SUGAYA, H

TETSUKA, I

SUZUKI, T

HARADA, T

机构：

[1] Second Department of Internal Medicine, Dokkyo University School of Medicine, Tochigi

[2] Second Department of Internal Medicine, Dokkyo University School Medicine, Mibu-cho, Tochigi 321-02

来源：

INTERNAL MEDICINE | 1992年 / 31卷 / 04期

关键词：

BENIGN BILIARY TRACT DISEASE; TUMOR MARKER;

D O I：

10.2169/internalmedicine.31.516

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 63-year-old male complainined of right upper abdominal pain and jaundice. Laboratory data on admission showed hyperbilirubinemia, elevation of biliary enzymes and an extraordinarily high value of serum CA19-9 (60,000 U/ml). Diagnostic imaging modalities including abdominal ultrasonogram, abdominal CT and PTC suggested a stone impaction of the common bile duct. Jaundice subsided after PTC-drainage in association with decreasing serum CA19-9 value, which returned to the normal level six weeks later. Spontaneous delivery of the stone via the fistula was confirmed by cholangiography through the drainage tube. Though there are few reports of such a high serum CA19-9 level, the possibility of benign biliary tract disease should be considered in patients showing an extraordinarily high serum CA19-9 value.

引用

页码：516 / 520

页数：5

共 19 条

[1]

Sawabu N., Satomura Y., Ota H., Et al., CA19–9 and CA125, Kan Tan Sui, 12, (1986)

[2]

Ishida M., Kajita Y., Nakajima Y., Et al., Clinical significance of new tumor associated antigen, CA19–9, Clin report, 17, (1983)

[3]

Tanemoto K., Konaga E., Takeuchi H., Et al., The clinical usefulness of carbohydrate antigen 19–9 (CA19–9) in various diseases, J Jpn Soc Clin Surg, 48, (1987)

[4]

Cyou M., Shiratori K., Watanabe S., Et al., Clinical significance of the tumor marker CA19–9 in carcinoma of pancreas, Tan To Sui, 6, (1985)

[5]

Ookura H., Sakawaki T., Clinical usefulness of CA19–9, Tan To Sui, 6, (1985)

[6]

Oguchi H., Homma T., Nagata A., Et al., Monoclonal antibody-defined tumor marker CA19–9: Evaluation of its clinical usefulness, using the radioimmunometric assey for CA19–9, Jpn J Gastroenterol, 81, (1984)

[7]

Shimada K., Kawaguchi T., Nambu F., Et al., Tumor marker for carcinoma of the pancreas with special referance to carbohydrate antigen 19–9, J Jpn Soc Clin Surg, 46, (1985)

[8]

Fuse Y., Tsuji M., Taniwaki M., Et al., Studies of clinical significance of serum CA19–9 in patients with cholelithiasis, Jpn J Gastroenterol, 83, (1986)

[9]

Hachiya T., Fukuyama T., Higuchi T., Et al., Serum levels of CA19–9 in various diseases of digestive system and its clinical significance, Nisseki Igaku, 37, (1985)

[10]

Sakai T., Kouno Y., Miura C., Et al., Evaluation of serum CA19–9 in various benign diseases, The Saishin Igaku, 40, (1985)

← 1 2 →